1. Home
  2. |Insights
  3. |Biosimilars Conference

Biosimilars Conference

Event | 11.18.09 - 11.19.09, 12:00 AM UTC - 12:00 AM UTC

With 20 speakers confirmed, this year’s Biosimilars conference is set to be jam-packed. Don’t miss the chance to:

  • Explore the latest developments in the US. What are the upcoming futures and challenges?
  • Revisit the EU Market. Learn what the growth drivers and restraints have been and what products to look out for
  • Evaluate the market from an innovator, biosimilar and dual perspective with presentations from Roche Pharma Research, Intas Pharmaceuticals and Merck Bioventures
  • Discover recent developments and comparability approaches to biosimilar mAbs. Learn the challenges and regulatory requirements that must be considered
  • Update your knowledge on advancements in biosimilar comparability, immunogenicity, formulation and pharmacokinetics
  • Analyse regulatory expectations on a Global basis and discover further information on development costs and the potential future impact in emerging markets
  • Ascertain what the payer’s perception is of the biosimilar market and the pricing and access environment for biosimilars
  • Familiarise yourself with patent law strategies and the ones to watch out for

Kristof Roox will speak about "Application of patent litigation strategies to biosimilars: is there a difference?".

Attachments

Participants

Insights

Event | 02.20.25

Has the Buss Stopped? Recoupment Today

Has the Buss Stopped? Recoupment Today: In 1997, the California Supreme Court decided Buss v. Superior Court. In Buss, the court concluded that a liability insurer that defended a mixed action could seek reimbursement from the insured for the defense costs associated with the claims that were not even potentially covered. Since then, numerous courts have held that insurers are entitled to recoup their defense costs associated with uncovered claims or causes of action. On the other hand, a significant number of courts have rejected insurers’ right to recoupment, at least in the absence of a policy provision granting the insurer that right. Some commentators have even suggested that the current judicial trend might be away from permitting insurers to recoup their defense costs. Is that correct? Has the Buss stopped? This panel of coverage experts will analyze insurers’ claimed right to recoupment today, and offer their perspectives on what the law on recoupment should perhaps be and might be in the future.

View All Insights